Poor CD4 recovery on suppressive HIV treatment tracks with coinfection and late presentation

Design

Systematic review and meta-analysis of observational studies, PRISMA 2020

Population

59 studies with 19,511 people with HIV and immunological non-response despite viral suppression

Primary outcome

Predictors of immunological non-response

Effect

Advanced HIV stage OR 2.66 (2.34 to 3.02); hepatitis C OR 1.85 (1.50 to 2.28); tuberculosis OR 1.77 (1.41 to 2.21)

A systematic review and meta-analysis of 59 observational studies, including 19,511 people with immunological non-response, looked for predictors of poor CD4 recovery despite virological suppression on antiretroviral therapy. Study quality was scored with the Newcastle-Ottawa Scale.

Advanced HIV stage had the strongest association (OR 2.66, 95% CI 2.34 to 3.02), followed by hepatitis C coinfection (OR 1.85, 1.50 to 2.28), tuberculosis (OR 1.77, 1.41 to 2.21), intravenous drug use (OR 1.67, 1.15 to 2.42), male sex (OR 1.33, 1.12 to 1.58) and hepatitis B coinfection (OR 1.30, 1.08 to 1.57). Older age and lower baseline and nadir CD4 counts were also linked. The review also listed 57 biomarkers as possible predictors.

These are associations in observational data with differing definitions of non-response, so they help identify who to watch, not how to treat them. The findings stress the cost of late presentation, which remains common in India.

• Look for coinfection with tuberculosis, hepatitis B and hepatitis C in anyone with poor CD4 recovery
• Expect slower recovery when baseline or nadir CD4 was very low
• Confirm that viral suppression is sustained and that adherence is real before labelling non-response
• Do not change an effective regimen because of CD4 count alone
• Earlier diagnosis and treatment remain the main way to avoid this problem

Why it matters

It points to modifiable or screenable factors, such as coinfections, behind patients who look controlled on viral load but not on CD4.

Don't overread it

Predictors are associations, and the review does not show that any intervention improves CD4 recovery.

The statistics, in plain English

Each odds ratio compares the odds of non-response in people with the factor against those without it; an odds ratio of 2.66 does not mean a 2.66 times higher risk when non-response is common. Pooling observational studies with different definitions of non-response adds heterogeneity that the abstract does not quantify.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.